Catch up on our webinar series!
Beyond sleepless nights: managing chronic insomnia in adults in primary care
- Available for a limited time only
Webinar 1 - Understanding chronic insomnia and its management
In this first webinar, Dr Lavan Baskaran – a GP from London – explores the science of sleep and diagnostic approaches for chronic insomnia. Dr Baskaran also uncovers the latest on QUVIVIQ™▼ (daridorexant), including its mechanism of action, clinical data, efficacy and safety.
Speaker
More webinars from the ‘Beyond sleepless nights: managing chronic insomnia in adults in primary care’ series coming at the end of October and November – come back to find out more!
Webinar 2 - Optimising consultations about sleep: case-based learning
Speaker
More webinars from the ‘Beyond sleepless nights: managing chronic insomnia in adults in primary care’ series coming at the end of November – come back to find out more!
Webinar 3 - Not just night sweats: exploring menopause and sleep
Speaker
Gain access to resources on chronic insomnia
Subscribe to get priority updates and access to videos, data and patient resources, plus details about us and our offerings.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
Works differently1,2
Is taken differently1,3
Is experienced differently1,4
Book an appointment
One of our product specialists would be happy to answer your questions.
QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed September 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
Photo by: kaboompics.com